BioSpace News Archive

The Automated And Closed Cell Therapy Processing Systems Market growth is on the back of the increasing popularity of regenerative medicines and cell therapies.

iOnctura SA, a clinical stage oncology company targeting core resistance and relapse mechanisms at the tumor-stroma-immune interface, is presenting clinical data confirming the mode of action of its autotaxin inhibitor IOA-289 and showing preclinical evidence of the role of autotaxin inhibition in breaking down tumor resistance mechanisms.

QIAGEN and Denovo Biopharma LLC announced a collaboration to develop a blood-based companion diagnostic test to identify patients expressing Denovo Genomic Marker 1 who are likely to respond to Denovo’s investigational cancer drug DB102TM for treatment of diffuse large B-cell lymphoma, one of the most common lymphoid cancers.

Anavo Therapeutics today announced the appointment of Charles McDermott as Chairman of the Board of Directors.

RhoVac AB, a Swedish cancer immunotherapy company, announces on December 9th, 2021, that its Data & Safety Monitoring Committee has conducted a planned interim safety review of its clinical phase IIb trial in prostate cancer, known as BRaVac.

Dr. Reddy’s Laboratories Ltd. announced the launch of Valsartan Tablets, USP, a therapeutic equivalent generic version of Diovan® Tablets approved by the U.S. Food and Drug Administration.

Faron Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on building the future of immunotherapy by harnessing the power of the immune system to tackle cancer and inflammation, announces topline biomarker data from the Phase I/II MATINS trial of bexmarilimab.

Affimed N.V. will host today a financial community call to discuss recent findings from the investigator sponsored trial (IST) at The University of Texas MD Anderson Cancer Center investigating the treatment of CD30-positive lymphoma patients with its innate cell engager (ICE®) AFM13, pre-complexed with cord blood-derived natural killer (cbNK) cells (AFM13-104).

ADMA Biologics, Inc. today announced that the European Patent Office (EPO) has issued European Patent No. 3375789, to the Company.

The new assay identifies positive COVID-19 cases and distinguishes between Alpha, Beta, Gamma, Delta, Omicron and its Stealth version.